Meeting
2014 Genitourinary Cancers Symposium
Results of a feasibility study of I-124 girentuximab in metastatic clear cell renal cell carcinoma (m ccRCC).
Authors
Stephen Michael Keefe
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
Stephen Michael Keefe , Mark Alan Rosen , Janelle Robinson , Karen McGibney , Amy Marshall , Ronac Mamtani , David J. Vaughn , Peter J. O'Dwyer , Naomi B. Haas , Daniel A. Pryma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT01253668
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 406)
DOI
10.1200/jco.2014.32.4_suppl.406
Abstract #
406
Poster Bd #
B8
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
STARLITE 2: Phase 2 study of nivolumab plus 177lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC).
First Author: Darren R. Feldman
Poster
2023 ASCO Genitourinary Cancers Symposium
89Zr-DFO-girentuximab for PET imaging of solid tumors likely to express high levels of carbonic anhydrase IX.
First Author: Andrei Iagaru
Poster
2021 ASCO Annual Meeting
Imaging HER2-positive metastatic esophagogastric cancer with 89Zr-trastuzumab PET and 18F-FDG PET.
First Author: Melissa Amy Lumish
Poster
2021 Genitourinary Cancers Symposium
MK-6482, a hypoxia-inducible factor 2α inhibitor (HIF-2α), versus everolimus in heavily pretreated, immune checkpoint–inhibitor-resistant, advanced clear cell renal cell carcinoma (ccRCC): Phase III study.
First Author: Toni K. Choueiri